FrancophonIA/ELRC3.0 huggingface dataset:
English: People who did not respond to the first dose can be given a second dose after at least four weeks.
Slovenian: Osebe, ki se niso odzvale na prvi odmerek, lahko drugi odmerek prejmejo po najmanj štirih tednih.
English: It is given according to official recommendations.
Slovenian: Cepivo se daje v skladu z uradnimi priporočili.
English: The European Commission granted a marketing authorisation valid throughout the European Union for M-M-RVaxPro on 5 May 2006.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom M-M-RVaxPro, veljavno po vsej Evropski uniji, izdala 5. maja 2006.
English: Under some special circumstances, it can also be used in babies as young as nine months.
Slovenian: V nekaterih posebnih okoliščinah se lahko uporablja tudi pri dojenčkih, starejših od devet mesecev.
English: They may also be given an additional vaccination against measles.
Slovenian: Dodatno so lahko cepljeni tudi proti ošpicam.
English: The full EPAR for M-M-RVaxPro can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo M-M-RVaxPro je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Injection site reactions were less common when the vaccine was injected into a muscle.
Slovenian: Reakcije na mestu injiciranja so bile manj pogoste, če je bilo cepivo injicirano v mišico.
English: Babies between nine and 12 months can be given the vaccine if they are considered to be at special risk, for example, if there is an outbreak in a day-care centre or the baby is travelling to an area where measles is common.
Slovenian: Dojenčki v starosti od devet do dvanajst mesecev se lahko cepijo, če se oceni, da so izpostavljeni posebnemu tveganju, če je na primer prišlo do izbruha bolezni v jaslih ali če dojenček potuje na območja, na katerih so ošpice pogoste.
English: This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo M-M-RVaxPro.
English: For people with thrombocytopenia (low blood platelet counts) or any problems with blood clotting, the vaccine should only be injected under the skin to avoid bleeding.
Slovenian: Ljudem s trombocitopenijo (nizko ravnjo trombocitov) ali težavami s strjevanjem krvi je treba cepivo injicirati samo pod kožo, da se prepreči krvavenje.
English: It is given as one dose injected into a muscle or under the skin, preferably in the thighs of younger children and the shoulder in older children and adults.
Slovenian: Daje se v enkratnem odmerku z injiciranjem v mišico ali pod kožo, pri mlajših otrocih v stegno, pri starejših otrocih in odraslih pa v ramenski predel.
English: When a person is given the vaccine, the immune system recognises the weakened viruses as ‘foreign' and makes antibodies against them.
Slovenian: Ko oseba prejme cepivo, imunski sistem prepozna oslabljene viruse kot tujke in proti njim razvije protitelesa.
English: What measures are being taken to ensure the safe and effective use of M-M-RVaxPro?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila M-M-RVaxPro?
English: A fourth study in 1,620 babies was carried out with ProQuad (a vaccine that contains similar weakened viruses to those of M-M-RVaxPro).
Slovenian: Četrta študija, ki je vključevala 1 620 dojenčkov, je bila izvedena z zdravilom ProQuad (cepivom, ki vsebuje podobne oslabljene viruse kot cepivo M-M-RVaxPro).
English: The CHMP decided that M-M-RVaxPro's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila M-MRVaxPro večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of M-M-RVaxPro have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila M-M-RVaxPro upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: M-M-RVaxPro is a vaccine.
Slovenian: Zdravilo M-M-RVaxPro je cepivo.
English: A second study in 1,997 children looking specifically at mumps showed that M-M-RVaxPro led to sufficient amounts of antibodies against mumps, while a third study in 776 children showed that immune responses triggered by M-M-RVaxPro were the same regardless of whether it was injected into a muscle or under the skin.
Slovenian: V drugi študiji, v katero je bilo vključenih 1 997 otrok in v kateri so zlasti proučevali mumps, je bilo dokazano, da je cepivo M-M-RVaxPro sprožilo zadostne količine protiteles proti mumpsu, medtem ko je tretja študija s 776 otroki pokazala, da so bili imunski odzivi, ki jih je sprožilo cepivo M-M-RVaxPro, enaki ne glede na to, ali je bilo cepivo injicirano v mišico ali pod kožo.
English: However, the immune response for measles was lower in babies who started vaccination at nine months.
Slovenian: Vendar pa je bil imunski odziv proti mumpsu manjši pri dojenčkih, ki so bili prvič cepljeni pri devetih mesecih.
English: The most common side effects with M-M-RVaxPro (seen in more than 1 patient in 10) are fever (38.5°C or higher), and injection site redness, pain and swelling.
Slovenian: Najpogostejši neželeni učinki cepiva M-M-RVaxPro (opaženi pri več kot 1 bolniku od 10) so povišana telesna temperatura (38,5 C ali višja) ter pordelost, bolečina in oteklina na mestu injiciranja.
English: Other information about M-M-RVaxPro
Slovenian: Druge informacije o zdravilu M-M-RVaxPro
English: M-M-RVaxPro must not be given during pregnancy, any illness with fever (over 38.5°C) or active untreated tuberculosis (TB).
Slovenian: Cepivo se ne sme uporabiti med nosečnostjo, katero koli boleznijo s povišano telesno temperaturo (nad 38,5°C) ali aktivno nezdravljeno tuberkulozo (TB).
English: For more information about treatment with M-M-Rvaxpro, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom M-M-RVaxPro preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The company that makes M-M-RVaxPro will continue to monitor the side effects to see if using recombinant albumin in the manufacturing process of M-M-RVaxPro leads to side effects such as allergic reactions.
Slovenian: Družba, ki izdeluje cepivo M-M-RVaxPro, bo spremljala neželene učinke, da bo ugotovila, ali uporaba rekombinantnega albumina v postopku izdelave cepiva povzroča neželene učinke, kot so alergijske reakcije.
English: M-M-RVaxPro should not be used in people who may be hypersensitive (allergic) to any measles, mumps or rubella vaccine, or to any of the ingredients, including neomycin (an antibiotic).
Slovenian: Cepiva M-M-RVaxPro ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) katero koli cepivo proti ošpicam, mumpsu in rdečkam ali katero koli sestavino zdravila, vključno z neomicinom (antibiotikom).
English: For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila M-M-RVaxPro naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: This study showed that, after the second dose, the production of antibodies against mumps and rubella in babies who started vaccination as young as nine months was similar to those of babies who started vaccination at 12 months.
Slovenian: V njej je bilo dokazano, da je bila po drugem odmerku tvorba protiteles proti mumpsu in rdečkam pri dojenčkih, ki so bili prvič cepljeni pri devetih mesecih, podobna ravnem, ki so jih opazili pri dojenčkih, ki so cepljenje začeli pri 12 mesecih.
English: It must also not be given to patients with certain blood or immune diseases.
Slovenian: Prav tako se ne sme uporabljati pri bolnikih s hudimi obolenji ledvic ali jeter.
English: In a study of 1,279 children, M-M-RVaxPro triggered the same level of immune response as a comparator vaccine, with more than 98% of vaccinated patients having sufficient levels of antibodies against the three viruses.
Slovenian: V prvi študiji, v katero je bilo vključenih 1 279 otrok, je cepivo sprožilo enake ravni imunskega odziva kot primerljivo cepivo, saj je več kot 98 % cepljenih oseb razvilo zadostne ravni protiteles proti vsem trem virusom.
English: What is M-M-RVaxPro and what is it used for?
Slovenian: Kaj je zdravilo M-M-RVaxPro in za kaj se uporablja?
English: M-M-RVaxPro is a vaccine used to protect adults and children aged 12 months or older against measles, mumps, and rubella (German measles).
Slovenian: Zdravilo M-M-RVaxPro je cepivo, ki se uporablja za zaščito odraslih in otrok, starejših od 12 mesecev, pred ošpicami, mumpsu in rdečkami (nemškimi ošpicami).
English: For the full list of all side effects reported with M-M-RVaxPro, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila M-M-RVaxPro, glejte navodilo za uporabo.
English: What benefits of M-M-RVaxPro have been shown in studies?
Slovenian: Kakšne koristi je zdravilo M-M-RVaxPro izkazalo v študijah?
English: What are the risks associated with M-M-RVaxPro?
Slovenian: Kakšna tveganja so povezana z zdravilom M-M-RVaxPro?
English: M-M-RVaxPro is available as a powder and solvent that are made up into a suspension for injection.
Slovenian: Zdravilo M-M-RVaxPro je prašek in vehikel za pripravo raztopine za injiciranje.
English: M-M-RVaxPro has been shown in studies to be effective at triggering the production of a sufficient amount of antibodies to protect against measles, mumps, and rubella.
Slovenian: V študijah je bilo dokazano, da je cepivo M-M-RVaxPro učinkovito pri sprožanju tvorjenja zadostne količine protiteles za zaščito pred ošpicami, mumpsom in rdečkami.
English: Why is M-M-RVaxPro approved?
Slovenian: Zakaj je bilo zdravilo M-M-RVaxPro odobreno?
English: M-M-RVaxPro contains small amounts of weakened forms of the viruses that cause measles, mumps, and rubella.
Slovenian: Cepivo M-M-RVaxPro vsebuje majhne količine oslabljenih oblik virusov, ki povzročajo ošpice, mumps in rdečke.
English: In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these viruses.
Slovenian: Ob ponovni izpostavitvi kateremu od teh virusnih sevov bo imunski sistem lahko hitreje tvoril protitelesa.
English: M-M-RVaxPro measles, mumps and rubella vaccine (live)
Slovenian: M-M-RVaxPro cepivo proti ošpicam, mumpsu in rdečkam (živo)
English: M-M-RVaxPro contains live attenuated (weakened) measles, mumps and rubella viruses.
Slovenian: Cepivo M-M-RVaxPro vsebuje žive, oslabljene viruse ošpic, mumpsa in rdečk.
English: How does M-M-RVaxPro work?
Slovenian: Kako zdravilo M-M-RVaxPro deluje?
English: How is M-M-RVaxPro used?
Slovenian: Kako se zdravilo M-M-RVaxPro uporablja?
English: It is not intended to provide practical advice on how to use M-M-RVaxPro.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: See examples below.
Slovenian: Glejte spodaj navedene primere.
English: (See sections 4.5 and 5.2)
Slovenian: (Glejte poglavji 4.5 in 5.2.)
English: No more injections will be given to you.
Slovenian: Injekcij ne boste več dobivali.
English: Especially tell your doctor if you are taking medicines for Parkinson's disease.
Slovenian: Še zlasti pa povejte svojemu zdravniku, če jemljete zdravila za Parkinsonovo bolezen.
English: The correct amount of solution will be injected into your muscle.
Slovenian: Pravilna količina raztopine bo injicirana v vašo mišico.
English: Solution (after reconstitution): 1 hour.
Slovenian: Raztopina (po pripravi): 1 ura.
English: Additional information on special populations
Slovenian: Dodatne informacije glede posebnih populacij
English: This leaflet was last revised in {month XXXX}
Slovenian: Navodilo je bilo nazadnje revidirano {mesec LLLL}
English: Rotate the vial until the contents have completely dissolved, giving a yellow coloured solution.
Slovenian: Vrtite vialo, dokler se vsebina popolnoma ne raztopi, kar da rumeno obarvano raztopino.
English: Do not use this medicine after the expiry date, which is stated on the carton.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
English: • Whenever the risk management system is modified,especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached
Slovenian: • ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji ali kadar je ta sprememba posledica tega, da je bil dosežen pomembnem mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
English: Volume of injection (ml)
Slovenian: Prostornina injekcije (ml)
English: Tell your doctor or nurse of your concern.
Slovenian: Povejte vašemu zdravniku ali medicinski sestri, kaj vas skrbi.
English: Your doctor will change your treatment to ZYPREXA tablets, as soon as appropriate.
Slovenian: Vaš zdravnik bo zamenjal vaše zdravljenje za ZYPREXA tablete, kakor hitro bo to primerno.
English: Your doctor will decide when you need a dose of ZYPREXA Injection.
Slovenian: Vaš zdravnik bo odločil, kdaj potrebujete odmerek ZYPREXA injekcije.
English: The dose is usually 10 mg for the first injection, but it may be less than this.
Slovenian: Odmerek za prvo injekcijo je običajno 10 mg, vendar je lahko tudi nižji.
English: • If you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6).
Slovenian: - če ste alergični na (preobčutljivi za) olanzapin ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
English: ZYPREXA powder for solution for injection should be reconstituted in accordance with the recommendation in section 6.6.
Slovenian: ZYPREXA prašek za raztopino za injiciranje je treba pripraviti v skladu s priporočili v poglavju 6.6.
English: The Cmax occurs earlier after intramuscular compared to oral use (15 to 45 minutes versus 5 to 8 hours).
Slovenian: Do Cmax pride prej po intramuskularni uporabi kot po peroralni uporabi (15 do 45 minut v primerjavi s 5 do 8 ur).
English: You should take your ZYPREXA tablets once a day following the advice of your doctor.
Slovenian: ZYPREXA tablete jemljite enkrat na dan, in sicer upoštevajte nasvet zdravnika.
English: Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking ZYPREXA and regularly during treatment.
Slovenian: Vaš zdravnik mora opraviti krvni test za preiskavo sladkorja v krvi in nivo določenih maščob pred začetkom jemanja zdravila ZYPREXA in redno tekom zdravljenja.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 27 September 1996 Date of latest renewal: 12 September 2006
Slovenian: Datum pridobitve dovoljenja za promet: 27. september 1996 Datum zadnjega podaljšanja dovoljenja za promet: 12. september 2006
English: If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Slovenian: Če vam je vaš zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred jemanjem tega zdravila posvetujte s svojim zdravnikom.
English: Powder: 3 years.
Slovenian: 6.3 Rok uporabnosti Prašek: 3 leta
English: Carnauba wax
Slovenian: karnauba vosek
English: Olanzapine is bound predominantly to albumin and α1-acid-glycoprotein.
Slovenian: Olanzapin se veže predvsem na albumin in α1-kisli glikoprotein.
English: Urinary incontinence, urinary retention
Slovenian: Urinska inkontinenca, zastajanje urina
English: ZYPREXA powder for solution for injection is intended for short term use only, for up to a maximum of three consecutive days.
Slovenian: ZYPREXA prašek za raztopino za injiciranje je namenjen samo za kratkotrajno uporabo, največ pa za tri zaporedne dni.
English: One carton contains 1 or 10 vial(s).
Slovenian: Ena škatla vsebuje 1 ali 10 vial.
English: A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Slovenian: A. IZDELOVALCI ZDRAVILA, ODGOVORNI ZA SPROŠČANJE SERIJ
English: However, the combination added to the somnolence observed with either medicines alone.
Slovenian: Vendar pa je kombinacija povečala zaspanost, ki je opažena pri vsakem od zdravil posebej.
English: • carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your ZYPREXA dose.
Slovenian: • karbamazepin (antiepileptik in stabilizator razpoloženja), fluvoksamin (antidepresiv) ali ciprofloksacin (antibiotik) - morda bo treba spremeniti vaš odmerek zdravila ZYPREXA.
English: Only a few doses of ZYPREXA Injection are needed.
Slovenian: Potrebnih je samo nekaj odmerkov ZYPREXA injekcije.
English: Do not freeze after reconstitution.
Slovenian: Po pripravi ne zamrzujte.
English: common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
Slovenian: < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (ocena ni možna iz danih podatkov).
English: In patients with Parkinson's disease ZYPREXA may worsen the symptoms.
Slovenian: Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo ZYPREXA poslabša simptome.
English: Based on the results of oral studies in mice and rats, it was concluded that olanzapine is not carcinogenic.
Slovenian: Na podlagi izsledkov študij peroralnega olanzapina na miših in podganah je bilo zaključeno, da olanzapin ni kancerogen.
English: If your doctor has to give a benzodiazepine injection to treat your condition, there should be at least a one hour time period after the ZYPREXA injection and you are to be monitored closely after the benzodiazepine injection is given.
Slovenian: Če vam mora vas zdravnik dati injekcijo benzodiazepina za zdravljenje vašega stanja, mora od dajanja injekcije zdravila ZYPREXA poteči vsaj ena ura in po prejetju injekcije benzodiazepina vas bo potrebno skrbno spremljati.
English: If you receive ZYPREXA injection, a benzodiazepine injection is not recommended at the same time as this may result in excessive sleepiness, may have serious effects on your heart rate or your breathing, and, in very rare cases, may result in death.
Slovenian: Če prejmete zdravilo ZYPREXA injekcija, ni priporočljivo sočasno dajanje injekcije benzodiazepina, saj to lahko povzroči pretirano zaspanost, ima lahko resne učinke na vaše srce ali dihanje ter v redkih primerih lahko povzroči smrt.
English: Tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Slovenian: Obvestite svojega zdravnika, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
English: ZYPREXA Injection is available in a pack containing 1 or 10 vial(s).
Slovenian: ZYPREXA injekcije so na voljo v pakiranjih po 1 ali 10 vial.
English: A common (≥ 1/100 to < 1/10) undesirable effect associated with the use of intramuscular olanzapine in clinical trials was somnolence.
Slovenian: Pogosti (≥ 1/100 do < 1/10) neželeni učinek, povezan z uporabo intramuskularnega olanzapina v kliničnih preskušanjih, je bila zaspanost.
English: Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Slovenian: Reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS)
English: 2 years.
Slovenian: 65 let.
English: • The use of ZYPREXA in elderly patients with dementia is not recommended as it may have serious side effects.
Slovenian: • Uporaba zdravila ZYPREXA ni priporočljiva pri starejših bolnikih z demenco, saj lahko povzroči resne neželene učinke.
English: ZYPREXA belongs to a group of medicines called antipsychotics and is used to treat the following conditions:
Slovenian: Zdravilo ZYPREXA spada v skupino zdravil, imenovanih antipsihotiki in se uporablja za zdravljenje naslednjih bolezni:
English: (tablet coating) macrogol and synthetic red iron oxide (E172)
Slovenian: (obloga tablete) makrogol in sintetični rdeči železov oksid (E172)
English: The following table provides injection volumes for delivering various doses of olanzapine:
Slovenian: Naslednja tabela kaže prostornine injekcij za injiciranje različnih odmerkov olanzapina:
English: A second injection, 5-10 mg, may be administered 2 hours after the first injection on the basis of individual clinical status.
Slovenian: Drugo injekcijo, 5-10 mg, lahko damo glede na individualno klinično stanje 2 uri po prvi injekciji.
English: Do not administer intravenously or subcutaneously.
Slovenian: Ne dajajte intravensko ali subkutano.
English: EXP Use solution within 1 hour
Slovenian: EXP Raztopino uporabite v 1 uri.
English: Your doctor will tell you how many ZYPREXA tablets to take and how long you should continue to take them.
Slovenian: Zdravnik vam bo povedal, koliko ZYPREXA tablet morate vzeti in kako dolgo naj bi jih jemali.
English: Parenteral medicines should be inspected visually for particulate matter prior to administration.
Slovenian: Parenteralna zdravila je treba pred dajanjem vizuelno preveriti, če vsebujejo delce snovi.
English: ZYPREXA is available in packs containing 28, 35, 56, 70 or 98 tablets.
Slovenian: Zdravilo ZYPREXA je na voljo v pakiranjih po 28, 35, 56, 70 ali 98 tablet.
English: For the same dose of olanzapine administered intramuscularly and orally, the associated area under the curve, half-life, clearance and volume of distribution are similar.
Slovenian: Za enak odmerek olanzapina, danega intramuskularno in peroralno, so si omenjena površina pod krivuljo, razpolovni čas, očistek in volumen distribucije podobni.
English: The exact amount is shown on your ZYPREXA tablet pack.
Slovenian: Natančna količina je navedena na ovojnini vaših ZYPREXA
English: It is extremely important that patients receiving intramuscular olanzapine should be closely observed for hypotension including postural hypotension, bradyarrhythmia and/or hypoventilation, particularly for the first 4 hours following injection and close observation should be continued after this period if clinically indicated.
Slovenian: Izredno pomembno je, da bolnike, ki prejemajo intramuskularni olanzapin, skrbno opazujemo zaradi možnosti hipotenzije, vključno s posturalno hipotenzijo, bradiaritmijo in/ali hipoventilacijo, posebno prve 4 ure po injekciji, natančno spremljanje pa nadaljujemo tudi dlje časa, če je to klinično indicirano.
English: Additional pharmacokinetic data following administration of oral olanzapine are described below.
Slovenian: Dodatni farmakokinetični podatki po dajanju peroralnega olanzapina so opisani spodaj.
English: • If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).
Slovenian: - če so vam v preteklosti ugotovili težave z očmi, kot je določena vrsta glavkoma (povišan tlak v očesu).
English: As with oral use, Cmax and area under the curve after intramuscular use are directly proportional to the dose administered.
Slovenian: Kot pri peroralni uporabi sta Cmax in površina pod krivuljo po intramuskularni uporabi neposredno sorazmerna danemu odmerku.
English: Other medicines and ZYPREXA
Slovenian: Druga zdravila in zdravilo ZYPREXA
English: Use the solution immediately within 1 hour of reconstitution.
Slovenian: Raztopino uporabite najkasneje v 1 uri po pripravi.
English: Children and adolescents ZYPREXA is not for patients who are under 18 years.
Slovenian: Otroci in mladostniki Zdravilo ZYPREXA ni namenjeno bolnikom, mlajšim od 18 let.